Source: Pharmacy Times articles
CARTITUDE-1 data show one-third of patients treated with cilta-cel
remain progression-free at 5 years without maintenance.
Recent Content
- Symptomatic progression-free survival as an emerging patient-centered endpoint in multiple myeloma: a secondary analysis of MagnetsiMM-3 trial data
- Blood Test Could Replace Bone Marrow Biopsies in Multiple Myeloma
- Value of serum-free light chain measurements in response and progression assessment in multiple myeloma with monoclonal protein measurable by electrophoresis
- Simultaneous whole-body multi-parametric 2-[18F]FDG-PET/MRI in smoldering multiple myeloma assessment: diagnostic and prognostic impact
- SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors
- Multiple Myeloma: A Modern Look at an Ancient Disease and 2025’s Therapeutic Breakthroughs
- Can Cilta-Cel Redefine Outcomes in Multiple Myeloma?
- Refining renal response assessment in monoclonal immunoglobulin deposition disease: Challenges, limitations and need for consensus
- Discontinuing Lenalidomide After ASCT May Be Safe for Select MRD-Negative Patients With Multiple Myeloma
- Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma